Discussion To date, the clinical development program suggests that lixisenatide has an appropriate pharmacodynamic action, with reductions in blood glucose, in particular marked reductions in PPG, manifesting as improvements in glycemic control, a beneficial effect on body weight, and with limited risk of hypoglycemia with 20 g OD dosing
Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies
Its like relying on a lower bank balanceyou might spend your available energy budget more quickly than youre accustomed to
2025 Jul 15;122(28):e2426564122
That third receptor is what makes retatrutide fundamentally different from everything currently available
Check the electronic Medicines Compendium (emc) at medicines.org.uk for UK-authorised product information, including Summaries of Product Characteristics (SmPCs) and Patient Information Leaflets, to confirm whether a medicine is licensed in the UK